C acid. Int J Oncol 2007; 30: 1181188. 43. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 2003; 63: 7291300. 44. Muhlethaler-Mottet A, Flahaut M, Bourloud KB, Auderset K, Meier R, Joseph JM et al. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent raise of the pro- to anti-apoptotic proteins ratio. BMC Cancer 2006; 6: 214. 45. Chung YL, Wang AJ, Yao LF. Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: implications for escalating therapeutic acquire in cancer radiotherapy. Mol Cancer Ther 2004; three: 31725. 46. Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, Ravdel L et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 2006; 66: 94450. 47. Wick W, Weller M, Weiler M, Batchelor T, Yung AW, Platten M. Pathway inhibition: emerging molecular targets for treating glioblastoma. Neuro Oncol 2011; 13: 56679. 48. Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001; 61: 3986997. 49. Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G. Response to epidermal growth issue receptor inhibitors in non-small cell lung cancer cells: restricted antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 2003; 9: 2316326. 50. Nakagawa T, Takeuchi S, Yamada T, Ebi H, Sano T, Nanjo S et al. EGFR-TKI resistance as a consequence of BIM polymorphism is usually circumvented in combination with HDAC inhibition. Cancer Res 2013; 73: 2428434. 51. Witta SE, Jotte RM, Konduri K, Neubauer MA, Spira AI, Ruxer RL et al. Randomized phase II trial of erlotinib with and with no entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. J Clin Oncol 2012; 30: 2248255. 52. Swanton C, Futreal A, Eisen T. Her2-targeted therapies in non-small cell lung cancer. Clin Cancer Res 2006; 12: 4377s383s. 53. Kim HJ, Litzenburger BC, Cui X, Delgado DA, Grabiner BC, Lin X et al. Constitutively active form I insulin-like development factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelialto-mesenchymal transition mediated by NF-kappaB and snail. Mol Cell Biol 2007; 27: 3165175. 54. Garcia S, Dales JP, Jacquemier J, Charafe-Jauffret E, Birnbaum D, Andrac-Meyer L et al.Zandelisib c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays.Ambrisentan Br J Cancer 2007; 96: 32935.PMID:35954127 55. Ma Computer, Kijima T, Maulik G, Fox EA, Sattler M, Griffin JD et al. c-MET mutational analysis in little cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 2003; 63: 6272281. 56. Ma Pc, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and tiny interfering RNA in non-small cell lung cancer. Cancer Res 2005; 65: 1479488. 57. Comoglio PM, Giordano S, Trusolino L. Drug improvement of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008; 7: 5041.
